1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Kaposi%s Sarcoma - Pipeline Review, H1 2015

Kaposi%s Sarcoma - Pipeline Review, H1 2015

  • January 2015
  • -
  • Global Markets Direct
  • -
  • 31 pages

Kaposi's Sarcoma - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Kaposi's Sarcoma - Pipeline Review, H1 2015’, provides an overview of the Kaposi's Sarcoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Kaposi's Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kaposi's Sarcoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Kaposi's Sarcoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Kaposi's Sarcoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Kaposi's Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Kaposi's Sarcoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Kaposi's Sarcoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Kaposi's Sarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Kaposi%s Sarcoma - Pipeline Review, H1 2015
Table of Contents
Introduction 4
Global Markets Direct Report Coverage 4
Kaposi's Sarcoma Overview 5
Therapeutics Development 6
Pipeline Products for Kaposi's Sarcoma - Overview 6
Pipeline Products for Kaposi's Sarcoma - Comparative Analysis 7
Kaposi's Sarcoma - Therapeutics under Development by Companies 8
Kaposi's Sarcoma - Therapeutics under Investigation by Universities/Institutes 9
Kaposi's Sarcoma - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Kaposi's Sarcoma - Products under Development by Companies 12
Kaposi's Sarcoma - Products under Investigation by Universities/Institutes 13
Kaposi's Sarcoma - Companies Involved in Therapeutics Development 14
Delenex Therapeutics AG 14
Kaposi's Sarcoma - Therapeutics Assessment 15
Assessment by Monotherapy Products 15
Assessment by Target 16
Assessment by Mechanism of Action 18
Assessment by Route of Administration 20
Assessment by Molecule Type 21
Drug Profiles 23
Antisense RNAi Oligonucleotides to Inhibit Rac 1 for Kaposis Sarcoma - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
CM-101 - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
DLX-1008 - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Small Molecule for Kaposi's Sarcoma - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
vif-1 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Kaposi's Sarcoma - Dormant Projects 29
Appendix 30
Methodology 30
Coverage 30
Secondary Research 30
Primary Research 30
Expert Panel Validation 30
Contact Us 31
Disclaimer 31

List of Tables

Number of Products under Development for Kaposi's Sarcoma, H1 2015 6
Number of Products under Development for Kaposi's Sarcoma - Comparative Analysis, H1 2015 7
Number of Products under Development by Companies, H1 2015 8
Number of Products under Investigation by Universities/Institutes, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 10
Comparative Analysis by Early Stage Development, H1 2015 11
Products under Development by Companies, H1 2015 12
Products under Investigation by Universities/Institutes, H1 2015 13
Kaposi's Sarcoma - Pipeline by Delenex Therapeutics AG, H1 2015 14
Assessment by Monotherapy Products, H1 2015 15
Number of Products by Stage and Target, H1 2015 17
Number of Products by Stage and Mechanism of Action, H1 2015 19
Number of Products by Stage and Route of Administration, H1 2015 20
Number of Products by Stage and Molecule Type, H1 2015 22
Kaposi's Sarcoma - Dormant Projects, H1 2015 29

List of Figures

Number of Products under Development for Kaposi's Sarcoma, H1 2015 6
Number of Products under Development for Kaposi's Sarcoma - Comparative Analysis, H1 2015 7
Number of Products under Development by Companies, H1 2015 8
Comparative Analysis by Early Stage Products, H1 2015 11
Assessment by Monotherapy Products, H1 2015 15
Number of Products by Top 10 Targets, H1 2015 16
Number of Products by Stage and Top 10 Targets, H1 2015 17
Number of Products by Top 10 Mechanism of Actions, H1 2015 18
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 19
Number of Products by Top 10 Molecule Types, H1 2015 21
Number of Products by Stage and Top 10 Molecule Types, H1 2015 22

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Lung Cancer: Analytical Tool

Lung Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

Brain Cancer: Analytical Tool

August 2016 $ 8096

Breast Cancer: Analytical Tool

August 2016 $ 8096

Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the US and South Korea

  • November 2016
    2 pages
  • Cancer  

  • United States  

    South Korea  

View report >

Therapy Market in the UK

  • November 2016
    11 pages
  • Therapy  

  • United Kingdom  

View report >

Cancer and Breast Cancer Statistics in the US

  • November 2016
    9 pages
  • Cancer  

    Breast Cancer  

    Cytokine  

  • United States  

View report >

Related Market Segments :

Cancer

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.